Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138218 | 0.82 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBGSK3A | |
| SCHEMBL21138186 | 0.78 | TP53 (0.31) | — | |
| SCHEMBL4750863 | 0.75 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBMAPK1 | |
| SCHEMBL21138498 | 0.72 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL24687442 | 0.67 | ADORA2A (0.36) | PI4KAPI4K2BPI4K2API4KBGSK3B | |
| SCHEMBL25344064 | 0.67 | PI4KA (0.33) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL4751440 | 0.66 | CYP11B1 (0.47) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4928331 | 0.65 | TP53 (0.49) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21138790 | 0.65 | ADORA2A (0.39) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4752076 | 0.64 | FDPS (0.43) | PI4KAPI4K2BPI4K2API4KBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | PI4KA 1612/4885PI4K2B 1818/4885PI4K2A 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.